M&A, People

Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout

Tesaro CEO Lonnie Moulder may not have landed the deal he originally wanted for selling the biotech, but he’s not exactly coming away empty-handed.

Lonnie Moulder

As part of their detailed look back at the deal, the biotech also revealed that Moulder will receive a total of $155,854,551 for his stock, options and RSU grant. President Mary Lynne Hedley gets $112,500,429.

Mary Lynne Hedley

That’s all substantially better than the rest of the executive crew, each of whom gets millions. Here’s the full roster from the SEC filing.

  • Timothy Pearson, CFO: $11.8 million
  • Grant Bogle, chief commercial officer: $5.3 million
  • Joseph Farmer, general counsel: $6.1 million
  • Martin Huber, chief medical officer: $7 million
  • Orlando Oliveira, general manager, international: $6 million

The top investor on Tesaro’s board was NEA, represented by David Mott, which gets $783 million in the buyout. Kleiner Perkins, which was represented by Beth Seidenberg, bags $167 million.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->